GLP-1 receptor agonists combined with metformin most effectively reduce weight and BMI in PCOSGLP-1 Combined With Metformin Shows Weight Loss For PCOS

Frontiers in Medicine Published July 3, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider GLP-1 and metformin combination as the most effective pharmacological option for weight and BMI reduction in PCOS.

This network meta-analysis evaluated the efficacy of GLP-1 receptor agonists, metformin, myoinositol, and their combinations in non-menopausal women with polycystic ovary syndrome (PCOS). The analysis focused on anthropometric and metabolic parameters to determine the most effective pharmacological interventions for weight management.

The authors found that the combination of GLP-1 and metformin was the most effective intervention for both body weight reduction (MD -5.58 kg; 95% CI -8.57 to -2.59) and BMI reduction (MD -2.17; 95% CI -2.77 to -1.58). GLP-1 monotherapy also showed significant reductions in weight (MD -5.22 kg), BMI (MD -2.00), and waist circumference (MD -4.70 cm). Notably, no significant effects were observed for HOMA-IR across any of the interventions.

The authors noted several limitations, including high heterogeneity in HOMA-IR results and a lack of data regarding reproductive, endocrine, and patient-centered outcomes. Because these broader clinical dimensions were not evaluated, the findings are limited to anthropometric and metabolic parameters. The results suggest that while GLP-1 plus metformin is effective for weight and BMI improvement in women with PCOS, further research is needed to assess its impact on other core symptoms of the condition.

How this fits prior evidence

This finding addresses a gap in pharmacological management for polycystic ovary syndrome by identifying specific combinations for anthropometric improvement. While previous evidence noted that total testosterone and BMI predict clomiphene citrate resistance in 6.8% of women with PCOS, this study focuses on weight reduction as a primary clinical goal. It also relates to the known use of metformin in metabolic contexts, though it specifically highlights the synergistic effect when combined with GLP-1 receptor agonists for weight loss.

Researchers analyzed several studies to compare different medications for women with polycystic ovary syndrome (PCOS). The study looked at three main options: GLP-1 receptor agonists, metformin, and myoinositol. These treatments were evaluated based on how well they helped patients manage body weight and BMI.

The results showed that combining GLP-1 receptor agonists with metformin was the most effective way to reduce body weight and lower BMI compared to other options. While GLP-1 drugs used alone also showed some weight loss, the combination performed better in these specific measurements. However, no significant changes were found for insulin resistance markers like HOMA-IR across any of the treatments.

It is important to note that this study only looked at physical measurements like weight and waist size. It did not measure how these drugs affected hormones, fertility, or overall patient well-being. Because the data on insulin resistance was inconsistent across studies, the results for those specific markers are less certain. Talk with a doctor to see which treatment fits your personal health goals.

What this means for you:

Combining GLP-1 receptor agonists and metformin may be more effective than other options for weight loss in PCOS.

Common questions

Which treatment is best for weight loss in PCOS?

The study found that combining GLP-1 receptor agonists with metformin was the most effective intervention for reducing body weight and BMI. While GLP-1 monotherapy also showed some reduction, the combination led to a mean weight decrease of 5.58 kg.

Does this treatment improve insulin resistance?

The study did not find any significant effects on HOMA-IR, which is a measure of insulin resistance, for any of the interventions tested. Because of high variability in these results, it is unclear if these medications impact that specific marker.

What other health factors were studied?

This study focused only on physical measurements like weight, BMI, and waist circumference. It did not evaluate how these treatments affect reproductive health, endocrine function, or other patient-centered outcomes for women with PCOS.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJul 2026

View Original Abstract ↓

BackgroundPolycystic Ovary Syndrome (PCOS) is a common endocrine disorder characterized by obesity, insulin resistance, and cardiometabolic risks. Lifestyle intervention is first-line therapy, but drug therapy is often necessary. Common treatments include metformin, myoinositol, and glucagon-like peptide-1 (GLP-1) receptor agonists. The comparative metabolic efficacy of these treatments remains unclear.MethodsWe conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) according to PRISMA-NMA guidelines. Eligible studies recruited non-menopausal women with PCOS and evaluated GLP-1 receptor agonists, metformin, or myoinositol (± folic acid [FA]) alone or in combination versus placebo or active comparators. The primary outcome was body weight change, while secondary outcomes included body mass index (BMI), waist circumference, and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). Outcomes were synthesized using a frequentist random-effects NMA, and the CINeMA framework was used to assess certainty.ResultsSixteen RCTs were included. GLP-1 + metformin was the most effective intervention for weight reduction (MD −5.58 kg; 95% CI −8.57 to −2.59) and BMI decrease (MD −2.17; 95% CI −2.77 to −1.58). GLP-1 monotherapy also showed decreases in weight (MD −5.22 kg) and BMI (MD −2.00). Waist circumference was significantly reduced by GLP-1 alone (MD −4.70 cm). None ofthe interventions showed significant effects on HOMA-IR, and results were marked by heterogeneity. Sensitivity analyses confirmed robustness for weight and BMI outcomes.ConclusionsGLP-1 receptor agonists combined with metformin appear to be the most effective pharmacologic therapies for anthropometric improvement, specifically body weight and BMI reduction, in women with PCOS. These conclusions are limited to anthropometric and metabolic parameters, reproductive, endocrine, and patient-centered outcomes were not evaluated in this analysis and therefore no claims of overall superiority in PCOS management can be made. Further long-term and head-to-head RCTs including a broader range of outcomes are needed.Systematic review registrationhttps://osf.io/zyhws/, identifier 10.17605/OSF.IO/ZYHWS

GLP-1 receptor agonists combined with metformin most effectively reduce weight and BMI in PCOSGLP-1 Combined With Metformin Shows Weight Loss For PCOS

How this fits prior evidence

Common questions

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

GLP-1 receptor agonists combined with metformin most effectively reduce weight and BMI in PCOSGLP-1 Combined With Metformin Shows Weight Loss For PCOS

How this fits prior evidence

Common questions

More on Polycystic Ovary Syndrome

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties